Xylem -- The Essentials

By Ken Smith • Monday, May 05 15:12 • Permanent Link

Xylem logged a -1.0% change during today's afternoon session, and is now trading at a price of $123.03 per share. The S&P 500 index moved -0.0%. XYL's trading volume is 791,151 compared to the stock's average volume of 1,856,901.

Xylem trades -11.28% away from its average analyst target price of $138.66 per share. The 17 analysts following the stock have set target prices ranging from $114.0 to $174.0, and on average have given Xylem a rating of buy.

Anyone interested in buying XYL should be aware of the facts below:

Xylem's current price is 105.3% above its Graham number of $59.91, which implies that at its current valuation it does not offer a margin of safety
Xylem has moved -10.7% over the last year, and the S&P 500 logged a change of 9.8%
Based on its trailing earnings per share of 3.72, Xylem has a trailing 12 month Price to Earnings (P/E) ratio of 33.1 while the S&P 500 average is 29.3
XYL has a forward P/E ratio of 25.9 based on its forward 12 month price to earnings (EPS) of $4.75 per share
Its Price to Book (P/B) ratio is 2.77 compared to its sector average of 2.89
Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for utility, industrial, and residential and commercial building services settings worldwide.
Based in Washington, the company has 23,000 full time employees and a market cap of $29.94 Billion. Xylem currently returns an annual dividend yield of 1.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.